EOSINOPHILS DISPLAY AN ACTIVATED PHENOTYPE IN CLINICALLY ACTIVE INFLAMMATORY BOWEL DISEASE
- EOSINOPHILS LOCALISE TO NERVES IN PATIENTS WITH IBD THROUGH SPECIFIC NEURALLY EXPRESSED ADHESION MOLECULES AND CHEMOATTRACTANTS. // Gut;Apr2004 Supplement 3, Vol. 53, pA99
The role of the eosinophil, which is a common inflammatory cell in inflamed gastrointestinal mucosa in inflammatory bowel disease (IBD) is uncertain. Using formolin fixed paraffin embedded tissue from patients who had previously undergone colonic resection for intractable IBD, the mechanisms of...
- Right Lower Quadrant Pain in a 2-Year-Old Boy. Heim-Hall, Josefine; Towell, Brian; Saldivar, Victor A. // Archives of Pathology & Laboratory Medicine;Jun2003, Vol. 127 Issue 6, pe269
Provides information on the case of a boy with right lower quadrant pain. Differential diagnosis of gastrointestinal eosinophilia; Nonparasitic causes of gastrointestinal eosinophilia; Definite diagnosis of angiostrongyliasis.
- Iron sucrose. // Reactions Weekly;8/28/2010, Issue 1316, p28
The article describes the case of a 43-year-old woman who developed eosinophilic fasciitis while receiving iron sucrose for iron-deficiency anemia.
- Therapy of the Hypereosinophilic Syndrome. Parrillo, Joseph E.; Fauci, Anthony S.; Wolff, Sheldon M. // Annals of Internal Medicine;Aug78, Vol. 89 Issue 2, p167
Deals with a study which analyzed the therapy and prognosis of patients with hypereosinophilic syndrome. Medical history of patients; Diagnostic evaluation of the patient; Response of patients to corticosteroid therapy.
- Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking phenytoin and levetiracetam: a case report. Hall, David Jeffrey; Fromm, Jason Steven // Journal of Medical Case Reports;2013, Vol. 7 Issue 1, p1
Introduction: Drug reaction with eosinophilia and systemic symptoms syndrome is a potentially life-threatening hypersensitivity reaction with rash, fever, and internal organ involvement, often hepatitis, occurring most commonly two to eight weeks after initiation of a medication. The present...
- Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Kühbacher, I.; Ott, S. J.; Helwig, U.; Mimura, T.; Rizzello, F.; Kleessen, B.; Gionchetti, P.; Blaut, M.; Campieri, M.; Fölsch, U. R.; Kamm, M. A.; Schreiber, S. // Gut;Jun2006, Vol. 55 Issue 6, p833
Background: The intestinal microbiota plays a critical role in the pathophysiology of pouchitis, a major complication after ileal pouch anal anastomosis in patients with ulcerative colitis. Recently, controlled trials have demonstrated that probiotics are effective in maintenance of remission in...
- Hypereosinophilic syndromes -- recent advances in definition, classification and therapeutic approach. Voican, Irina; Vladareanu, Ana Maria; Dervesteanu, Mihaela // Maedica - a Journal of Clinical Medicine;2009, Vol. 4 Issue 2, p146
Hypereosinophilic syndromes are a heterogeneous group of disorders with low incidence, characterized by eosinophil blood count higher than 1,5x109/L persistent for at least 6 months in the absence of a reactive cause and with signs and symptoms of organ involvement due to the eosinophilia itself...
- Interleukin-5, Eosinophilic Diseases and Therapeutic Intervention. Zabeau, Lennart; Gevaert, Philippe; Bachert, Claus; Tavernier, Jan // Current Drug Targets - Inflammation & Allergy;Dec2003, Vol. 2 Issue 4, p319
Interleukin 5 (IL-5) is the key cytokine in an eosinophil's life span: it supports eosinophilopoiesis and eosinophil differentiation, contributes to eosinophil migration, tissue localisation and function, and prevents eosinophil apoptosis. Given the likely role of eosinophils in chronic...
- The Hypereosinophilic Syndrome and the Biology of Cancer. Schwartz, Robert S. // New England Journal of Medicine;3/27/2003, Vol. 348 Issue 13, p1199
Reports on a study of hypereosinophilic syndrome. Eosinophilia, which is a rare condition that is not well understood; Cancer patients who develope hypereosinophilic syndrome; Treatments and research concerning the syndrome.